Hyderabad-based biopharmaceutical company Suven Life Sciences has informed that it has been granted two product patents in Russia and Australia for two of their new chemical entities (NCEs). These patents are valid until 2023.

The granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts.

These patents are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like attention deficient hyperactivity,

Alzheimer's, Parkinson, Schizophrenia and Huntington's.

The company’s net profit declined 33.3% to Rs 1.94 crore on 24.4% growth in net sales to Rs 35 crore in Q4 March 2008 over Q4 March 2007.